Pipeline
-
Code nameCellsTarget diseasesProductPhaseResearchDevelopmentSale
-
-
IMTR001
- CD62L low
- Cancer
- diagnostic agent, therapeutic drug
-
Research DevelopmentLicense out
-
-
-
IMTR002
- Th7R
- Cancer
- diagnostic agent, therapeutic drug
-
Research DevelopmentLicense out
-
-
-
IMTR003
- Th7R
- Covid-19
- diagnostic agent
-
Research Development
-
-
-
IMTR004
- (unrevealed...)
- (unrevealed...)
- diagnostic agent
-
Research
-
IMTR001Development of diagnostic methods to pre-predict the efficacy of PD-1 antibodies in cancer therapy.
We have developed a highly specific and sensitive method to predict the effect of immune checkpoint inhibitors (Nivolumab) by examining lymphocytes in the blood.
The method has several advantages: It does not use cancer tissue, is relatively inexpensive, analyzed quickly and are already used in clinical trials.
Patent No. 6664684
Joint research with Professor Hiroshi Kagami of Saitama Medical University.
IMTR002Biomarkers for predicting response to cancer therapy. (Th7R)
The study on a new immune cell (Th7R), CCR4-CCR6 + CD4+ T cells, discovered it is possible to predict the effects of immune checkpoint inhibitors, PD-1 inhibitors or PD-L1 inhibitors, more easily and with higher sensitivity and specificity than ever before using blood.
Patent No. 7175068
Joint research with Professor Hiroshi Kagami of Saitama Medical University.
IMTR003COVID-19 Biomarker for predicting symptoms of pneumonia.
The measurement of the number of immune cells in the blood was found to be effective in predicting the severity of pneumonia in COVID-19.
Patent pending
Joint research with Professor Hiroshi Kagami of Saitama Medical University.